XML 21 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Total National Health Investors, Inc. Stockholders’ Equity
Common Stock
Capital in Excess of Par Value
Retained Earnings
Cumulative Dividends
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2023     43,409,841        
Beginning balance at Dec. 31, 2023 $ 1,264,391 $ 1,253,952 $ 434 $ 1,603,757 $ 2,466,844 $ (2,817,083) $ 10,439
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income, excluding loss attributable to redeemable noncontrolling interest 94,574 94,743     94,743   (169)
Share-based compensation expense $ 3,512 3,512   3,512      
Grants of restricted stock awards (in shares)     15,000        
Shares issued due to stock options exercised (in shares) 1,065,119   197,453        
Shares issued due to stock options exercised $ 2 2 $ 2        
Shares withheld for net settlement of stock incentive awards (in shares)     (230)        
Taxes paid related to net settlement of stock incentive awards (5,819) (5,819)   (5,819)      
Noncontrolling interest capital contribution 70           70
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interest (807)           (807)
Dividends declared, per common share (117,440) (117,440)       (117,440)  
Ending balance (in shares) at Sep. 30, 2024     43,622,064        
Ending balance at Sep. 30, 2024 1,238,483 1,228,950 $ 436 1,601,450 2,561,587 (2,934,523) 9,533
Beginning balance (in shares) at Jun. 30, 2024     43,442,849        
Beginning balance at Jun. 30, 2024 1,254,303 1,244,417 $ 434 1,606,199 2,533,047 (2,895,263) 9,886
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income, excluding loss attributable to redeemable noncontrolling interest 28,486 28,540     28,540   (54)
Share-based compensation expense 670 670   670      
Shares issued due to stock options exercised (in shares)     179,215        
Shares issued due to stock options exercised 2 2 $ 2        
Taxes paid related to net settlement of stock incentive awards (5,419) (5,419)   (5,419)      
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interest (299)           (299)
Dividends declared, per common share (39,260) (39,260)       (39,260)  
Ending balance (in shares) at Sep. 30, 2024     43,622,064        
Ending balance at Sep. 30, 2024 $ 1,238,483 1,228,950 $ 436 1,601,450 2,561,587 (2,934,523) 9,533
Beginning balance (in shares) at Dec. 31, 2024 45,687,942   45,687,942        
Beginning balance at Dec. 31, 2024 $ 1,375,387 1,366,475 $ 457 1,736,831 2,604,829 (2,975,642) 8,912
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income, excluding loss attributable to redeemable noncontrolling interest 103,707 104,014     104,014   (307)
Issuance of common shares, net (in shares)     1,891,021        
Issuance of common shares, net 134,923 134,923 $ 19 134,904      
Equity issuance costs (153) (153)   (153)      
Share-based compensation expense $ 4,612 4,612   4,612      
Grants of restricted stock awards (in shares)     29,500        
Shares issued due to stock options exercised (in shares) 185,446   31,226        
Shares withheld for net settlement of stock incentive awards (in shares)     (1,187)        
Taxes paid related to net settlement of stock incentive awards $ (415) (415)   (415)      
Noncontrolling interest capital contribution 306           306
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interest (623)           (623)
Reversal of previously declared distributions to noncontrolling interest upon liquidation 298           298
Purchase of noncontrolling interest 0 21   21     (21)
Dividends declared, per common share $ (128,578) (128,578)       (128,578)  
Ending balance (in shares) at Sep. 30, 2025 45,687,942   47,638,502        
Ending balance at Sep. 30, 2025 $ 1,489,464 1,480,899 $ 476 1,875,800 2,708,843 (3,104,220) 8,565
Beginning balance (in shares) at Jun. 30, 2025     47,473,160        
Beginning balance at Jun. 30, 2025 1,487,973 1,479,645 $ 475 1,863,582 2,675,981 (3,060,393) 8,328
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income, excluding loss attributable to redeemable noncontrolling interest 32,765 32,862     32,862   (97)
Issuance of common shares, net (in shares)     154,673        
Issuance of common shares, net 11,439 11,439 $ 1 11,438      
Share-based compensation expense 983 983   983      
Shares issued due to stock options exercised (in shares)     10,669        
Taxes paid related to net settlement of stock incentive awards (224) (224)   (224)      
Noncontrolling interest capital contribution 250           250
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interest (193)           (193)
Reversal of previously declared distributions to noncontrolling interest upon liquidation 298           298
Purchase of noncontrolling interest 0 21   21     (21)
Dividends declared, per common share $ (43,827) (43,827)       (43,827)  
Ending balance (in shares) at Sep. 30, 2025 45,687,942   47,638,502        
Ending balance at Sep. 30, 2025 $ 1,489,464 $ 1,480,899 $ 476 $ 1,875,800 $ 2,708,843 $ (3,104,220) $ 8,565